Qurient Co., Ltd.

Company Profile

Sector

Healthcare

Industry

Biotechnology

Employees

N/A

Website

www.qurient.com

Country

South Korea

Exchange

KOSDAQ

Founded 2008Seongnam-si, South Korea

Qurient Co., Ltd., a biotech company provides the research and development of drugs to address unmet medical needs in Korea and globally. The company's pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as tuberculosis/non-TBM.

Its pipeline products also comprise Adrixetinib (Q702), an Axl/Mer/CSF1R Inhibitor, which completed phase I for the treatment of solid tumors Q901, a selective CDK7 inhibitor, is under Phase I stage for treating solid tumors. Founded in 2008 and headquartered in Seongnam-si, South Korea, Qurient was formerly known as Quro Science Inc. before rebranding in October 2011.

Key Stats

52-Week Range

₩9520.00₩62900.00

Beta0.36

Trailing P/EN/A

Forward P/EN/A

Trailing EPSN/A

Avg Volume

Earnings & Analyst

Next EarningsN/A

EPS EstimateN/A

Target Mean PriceN/A

RecommendationNone

Recommendation MeanN/A

Recent SEC Filings

SEC filings for this ticker are not available yet.